Author

Gerardo Rodriguez‐Araujo

Observed names: Gerardo Rodriguez-Araujo, Gerardo Rodriguez-araujo, Rodriguez‐Araujo, Gerardo

Observed institutions: AbbVie (United States), Arkansas Heart Hospital, University of Arkansas for Medical Sciences, The University of Osaka

OpenAlex ID: A5085538125

Essential Role for miR-196a in Brown Adipogenesis of White Fat Progenitor Cells

2012 · Masaki Mori, Hironori Nakagami, et al. · PLoS Biology · 243

PDF

Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study

2023 · Quentin M. Anstee, Brent A. Neuschwander-Tetri, et al. · Clinical Gastroenterology and Hepatology · 176

Pathophysiology of cardiovascular disease in diabetes mellitus

2018 · Gerardo Rodriguez-Araujo, Hironori Nakagami · Cardiovascular Endocrinology & Metabolism · 95

Del Nido cardioplegia in low risk adults undergoing first time coronary artery bypass surgery

2016 · Gustavo E. Guajardo Salinas, Roger Nutt, et al. · Perfusion · 83

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

2023 · Quentin M. Anstee, Kathryn J. Lucas, et al. · Hepatology · 72

Alpha-synuclein elicits glucose uptake and utilization in adipocytes through the Gab1/PI3K/Akt transduction pathway

2012 · Gerardo Rodriguez-Araujo, Hironori Nakagami, et al. · Cellular and Molecular Life Sciences · 54

Low alpha-synuclein levels in the blood are associated with insulin resistance

2015 · Gerardo Rodriguez-Araujo, Hironori Nakagami, et al. · Scientific Reports · 45

PDF

Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

2024 · Carlo Di Lorenzo, Julie Khlevner, et al. · The Lancet. Gastroenterology & hepatology · 33

PDF

Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis

2024 · Sven M. Francque, Alexander Hodge, et al. · Hepatology Communications · 15

Same versus next day discharge after elective transradial PCI: The RAdial SAme Day DischArge after PCI trial. (The RASADDA-PCI trial)

2018 · Gerardo Rodriguez-Araujo, Mehmet Cilingiroglu, et al. · Cardiovascular revascularization medicine · 14

Immediate and intermediate-term results of optical coherence tomography guided atherectomy in the treatment of peripheral arterial disease: Initial results from the VISION trial

2016 · Ian Cawich, Andre R.M. Paixao, et al. · Cardiovascular revascularization medicine · 11

Randomized controlled trial of linaclotide in children aged 6−17 years with functional constipation

2024 · Carlo Di Lorenzo, Samuel Nurko, et al. · Journal of Pediatric Gastroenterology and Nutrition · 9

PDF

Safety and efficacy of linaclotide in children aged 7–17 years with irritable bowel syndrome with constipation

2023 · Carlo Di Lorenzo, Samuel Nurko, et al. · Journal of Pediatric Gastroenterology and Nutrition · 9

PDF

Safety and efficacy of linaclotide in children aged 2–5 years with functional constipation: Phase 2, randomized study

2024 · Carlo Di Lorenzo, Jon Robert, et al. · Journal of Pediatric Gastroenterology and Nutrition · 7

PDF

Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists

2020 · Gerardo Rodriguez-Araujo · Cardiovascular Endocrinology & Metabolism · 6

Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development

2017 · Andrew J. Krentz, Gerardo Rodriguez-Araujo · Pharmaceutical Medicine · 3

145 Efficacy and Safety of Linaclotide in Treating Functional Constipation in Pediatric Patients Aged 6-17 Years: a Phase 3 Pivotal Randomized Placebo-controlled Trial

2023 · Carlo Di Lorenzo, Samuel Nurko, et al. · Gastroenterology · 2

PDF

Mo2015 SAFETY OF LINACLOTIDE IN PEDIATRIC PATIENTS WITH FUNCTIONAL CONSTIPATION: A POOLED ANALYSIS OF PLACEBO-CONTROLLED RANDOMIZED-CONTROLLED TRIALS

2023 · Jeffrey S. Hyams, Miguel Saps, et al. · Gastroenterology · 1

Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH

2019 · Gerardo Rodriguez-Araujo, Andrew J. Krentz · Springer eBooks · 1

Publisher Correction: Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development

2018 · Andrew J. Krentz, Gerardo Rodriguez-Araujo · Pharmaceutical Medicine · 1

PDF

LBT-7 Feasibility And Clinical Importance Of Same Versus Next Day Discharge After Elective Transradial Percutaneous Coronary Intervention, The Rasadda-pci Trial

2017 · William Rollefson, Mehmet Cilingiroglu, et al. · JACC: Cardiovascular Interventions · 1

PDF

Mo1757 SAFETY AND EFFICACY OF LINACLOTIDE IN PEDIATRIC PATIENTS AGED 2–5 YEARS WITH FUNCTIONAL CONSTIPATION (FC): RESULTS FROM AN OPEN-LABEL SAFETY EXTENSION OF A PHASE 3 STUDY

2026 · Carlo Di Lorenzo, Miguel Saps, et al. · Gastroenterology

Mo1757 SAFETY AND EFFICACY OF LINACLOTIDE IN PEDIATRIC PATIENTS AGED 2–5 YEARS WITH FUNCTIONAL CONSTIPATION (FC): RESULTS FROM AN OPEN-LABEL SAFETY EXTENSION OF A PHASE 3 STUDY

2026 · Carlo Di Lorenzo, Miguel Saps, et al. · Gastrointestinal Endoscopy

624: Efficacy and Safety of Linaclotide in Treating Pediatric Patients Aged 7–17 Years With Irritable Bowel Syndrome With Constipation (ibs-c): Results From a Phase 3 Study

2025 · Jeffrey S. Hyams, Miguel Saps, et al. · Gastroenterology

Sa2099: LONG-TERM SAFETY OF LINACLOTIDE IN TREATING PEDIATRIC PATIENTS AGED 7–17 YEARS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C): INTERIM RESULTS FROM A PHASE 3 STUDY

2025 · Miguel Saps, Samuel Nurko, et al. · Gastroenterology

Works count: 31

Citation count: 881

H-index: 11

I10-index: 11